eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2016
 
Share:
Share:
more
 
 
Original paper

Combined use of biochemical and volumetric biomarkers to assess the risk of conversion of mild cognitive impairment to Alzheimer’s disease

Marta Nesteruk, Tomasz Nesteruk, Maria Styczyńska, Monika Mandecka, Anna Barczak, Maria Barcikowska

Folia Neuropathol 2016; 54 (4): 369-374
Article file
- Combined.pdf  [0.10 MB]
 
 

Introduction

Mild cognitive impairment (MCI) was treated in the past as a transitional state between the physiological aging and dementia. Currently it is a separate diagnosis, although very heterogeneous. It requires clinical vigilance because of possibility of conversion to dementia, most often to Alzheimer’s disease (AD), with an average of 7-15% per year. The moment of conversion is very important due to the possibility of therapeutic effects, which are most effective in the early stages of AD, while the recommended treatment of MCI does not exist. Criteria for diagnosis of AD (NIA/AA, 2011) [1] include not only the dementia phase but also the MCI phase and preclinical phase of Alzheimer’s disease pathophysiological process, when pathological changes are present in the brain but the patient does not have any clinical symptoms. Such state can last for even twenty years.
Although “amyloid cascade hypothesis” has given rise to doubts [2], diagnostic criteria of MCI from 2011 indicate the important role of biomarkers [1]. Biomarkers can improve the prediction of MCI conversion to AD. Significant markers include markers of -amyloid (A) deposition (decreased level of A1-42 in the cerebrospinal fluid (CSF) or positive amyloid imaging in PET) and markers of neuronal injury (increased levels of tau protein- total and/or phosphorylated in CSF or decreased glucose uptake in the temporal-parietal area in FDG-PET or reduced volume of hippocampus in magnetic resonance imaging – MRI) [1]. Currently, these parameters are not used in clinical practice because of the lack of treatment of MCI due to AD. However, positive biomarkers increase the likelihood that the cognitive impairment can be caused by the pathophysiological process of AD [9]. In such case the probability of MCI conversion to AD in the future is higher.
The aim of our study was to evaluate the usefulness of several biomarkers in predicting the conversion of MCI to AD: -amyloid and tau proteins in the CSF and volumetric evaluation of different brain structures including the hippocampus in MRI.

Material and methods

The study population was 40 patients (22 women and 18 men), aged 50-80 years, with MCI diagnosed in the Alzheimer’s Department (according to the diagnostic criteria from 2004; Winblad et al.) [16]. The Mini Mental State Examination (MMSE) [7], neurological and neuropsychological assessments (using standard neuropsychological tests) were performed; on CDR scale all patients received 0.5 [10]. Laboratory tests were taken to exclude other causes of cognitive impairment. Brain MRI was performed for all patients on a 1.5 T Toshiba apparatus to calculate volumes of selected structures (hippocampus, entorhinal cortex, posterior cingulate gyrus, parahip­pocampal gyrus, superior, medial, inferior temporal gyri and total intracranial volume) using FreeSurfer software. Each volume (hippocampus, entorhinal cortex, posterior cingulate gyrus, parahippocampal gyrus, superior, medial, inferior temporal gyri) was divided by the total intracranial volume to normalize results and to eliminate differences in the brain size (according to Whitwell) [15]. All volumes were multiplied by 1000 in order to facilitate comparison between them. Each patient had a lumbar puncture to evaluate A and tau protein (total and phosphorylated) in the cerebrospinal fluid. There was a 2-year observation period. During control visits, MMSE, neurological and neuropsychological examinations were performed to assess potential disease progression to AD. Alzheimer’s disease was recognized on the basis of the diagnostic criteria NIA/AA, 2011 [1].
Patients diagnosed with conversion to AD had been treated with the acetylcholinesterase inhibitor. All patients have remained under the care of our Memory Disorders Outpatient Clinic and have had periodical follow-up visits.

Results

Amongst 40 patients with MCI, 9 (22.5%) converted to AD within 2 years of observation (on average 9.2 months, SD 5.8). The study population was divided into two subgroups: subgroup 1: non-converters, who did not convert to AD (31 patients) and subgroup 2: converters, who converted to AD (9 patients). The characteristics of subgroups, including the results of CSF are shown in Table I, together with the cut-off points (established in our laboratory, described in our previous study [8]).
On the basis of our laboratory cut-offs the most corresponding was A1-42 value, which was positive for 7 of 9 (77.8%) converters but for 13 of 31 nonconverters it was false positive. A positive value for total tau protein was obtained for 6 of 9 (66.7%) converters and the value false positive for 11 patients with stable MCI. The result of phosphorylated tau protein was positive only for 33% of converters. Table II presents descriptive statistics for all measured structures in MRI – average normalized values were multiplied by 1000 for easier data comparison.
Table III shows the results the Student’s t-test significance of differences between subgroups for independent samples.
Statistically significant values were obtained for the left hippocampus, right hippocampus, left entorhinal cortex, right inferior temporal gyrus and A (p ≤ 0.05). Discriminant analysis model used all volumetric measurements and values of A and total tau to determine subgroup membership: converter or non-converter. Discriminant analysis was conducted in three steps: for volumetric measurements only, for A and total tau (phosphorylated tau was excluded because of high p-value) and for volumetry and CSF biomarkers. Sensitivity for MCI conversion to AD on the basis of volumetric measurements was 88.9% and specificity 90.3%. On the basis of A and total tau sensitivity was 77.8% and specificity 83.9%. The percentage of correct classification using the results of the volumetric measurement was 90%, and by using A and total tau 82.5%. The results of the volumetric measurements together with results of the proteins in the CSF did not increase the sensitivity (88.9%) but increased specificity to 96.8% and the percentage of correct classification to 95%. Sensitivity, specificity and the percentage of correct classification for parameters which were statistically significant are presented in Table IV.

Discussion

The obtained results confirm that the use of volumetric assessment of selected brain structures and the assessment of Aand tau protein in CSF can be useful in predicting the MCI progression to AD. However, the biggest limitation of our study was the small group of patients (40 persons), so the results are limited. Surprisingly, sensitivity for volumetric measurements was almost 90%, whereas in our previous study (101 patients diagnosed with MCI) we have obtained sensitivity of 64.7%, specificity of 96.4% and classification rate of 91% (in this study 90%) [11]. Similar results using volumetry were presented by Convit. His study group was also limited (46 patients); sensitivity of the prediction of conversion by using volume of hippocampus was 57% (in our study 66.7%) and by using all measured volumes increased to 93% (in our study to 88.9%), specificity was 97% (in our study 90.3%) [3]. Taking into account individual volumetric measurements the results obtained in our previous study were confirmed, i.e. the highest sensitivity was for the hippocampus and then for the left entorhinal cortex [11]. Our results are contrary to the results presented by Dickerson (23 patients diagnosed with MCI, observation period of 12-77 months) or Stoub (23 patients diagnosed with MCI and 35 from the control group, observation period was 5 years) in whose studies volume of entorhinal cortex was a better parameter than volume of hippocampus in predicting MCI conversion to AD [4,13]. It should be noted that higher sensitivity compared to single volumetric measurements, was obtained for A (77.8%), as in Egli’s study, and as for total tau it was the same as for hippocampi (66.7%) but total tau has had higher specificity compared with A and hippocampi which gives the best percentage of correct classification (conversion vs. no conversion) for total tau protein (80%). Specificity increased after using a few parameters together [5].
Biomarkers were also studied in Ewers’ study; the most sensitive parameter was volumetric measurement of left hippocampus and the highest percentage of correct classification was achieved by using the right entorhinal cortex volume. Sensitivity and specificity of prediction of MCI conversion to AD increased in the models using parameters of cerebrospinal fluid [6].
The study which used ADNI database [14] on 162 patients with diagnosed MCI showed superiority of the biomarkers from CSF in predicting the conversion of MCI to AD (sensitivity 76.4% vs. 65.4%), the percentage of correct classification for both markers was the same (65.4%) but increased (to 68.5%) using both methods together (follow-up period of 36 months).
In Prestia’s study the highest sensitivity was for A (79%) as a single biomarker, which was also confirmed in our work, with the highest specificity for the volumetric measurement of hippocampus (76%). The study group consisted of 103 patients diagnosed with MCI (from two databases: ADNI and TOMC and follow-up period was 36 ± 12 months) [12].
The follow-up period for our study was 2 years and there is a possibility that in the coming years progression to AD in subsequent patients can be observed, so the proportion of converters to nonconverters can change and sensitivity of used methods can also improve. The patients enrolled in our study met the MCI criteria [16]; conversion to AD was diagnosed in the patients who progressed to dementia and met criteria for probable AD [9] but evenin such a small group there is a probability of a mistake in diagnosis (other type of dementia for example FTD, DLB).

Conclusions

The above-mentioned biomarkers seem to be important parameters, in particular when biochemical biomarkers are used together with volumetric ones. Possibility of CSF analysis with A and tau protein assessment is nowadays easier. MRI is also widely available. Confirmation of effectiveness of the method requires the study and observation on a larger group of patients with diagnosed MCI.

Disclosure

Authors report no conflict of interest.

References

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-279.
2. Armstrong RA. A critical analysis of the ‘amyloid cascade hypothesis’. Folia Neuropathol 2014; 52: 211-225.
3. Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease. Neurobiol Aging 2000; 21: 19-26.
4. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Aging 2001; 22: 747-754.
5. Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample. J Alzheimers Dis 2015; 44: 625-633.
6. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H; North American Alzheimer’s Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012; 33: 1203-1214.
7. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-189.
8. Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T. Association between Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease. J Alzheimers Dis 2016; 54: 157-168.
9. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-269.
10. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
11. Nesteruk M, Nesteruk T, Styczyńska M, Barczak A, Mandecka M, Walecki J, Barcikowska-Kotowicz M. Predicting the conversion of mild cognitive impairment to Alzheimer’s disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging. Neurol Neurochir Pol 2015; 49: 349-353.
12. Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust WJ, Frisoni GB. Translational Outpatient Memory Clinic Working Group; Alzheimer’s Disease Neuroimaging Initiative. Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimers Dement 2013; 9: 677-686.
13. Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, deToledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005; 64: 1520-1524.
14. Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer’s disease and prediction of mild cognitive impairment conversion. Neuroimage 2012; 62: 229-238.
15. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001; 22: 1483-1489.
16. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
Copyright: © 2016 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2017 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe